Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs DM 199 (Primary) ; DM 199 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms REMEDY; Remedy1
- Sponsors DiaMedica Therapeutics
- 14 Mar 2022 According to a DiaMedica Therapeutics media release, data from this study will be presented at the American Heart Association 2022 International Stroke Conference.
- 11 Feb 2022 Results of post-hoc analysis assessing the effect of DM199 on the rate of stroke recurrence during a 90-day follow-up. Stroke recurrence after a primary stroke is associated with longer hospitalization and increased neurologic disability and death, presented at the International Stroke Conference 2022.
- 25 Jan 2022 According to a DiaMedica Therapeutics media release, data from this study will be presented at the American Heart Association 2022 International Stroke Conference.